Cryoballoon pulmonary vein isolation in a patient with atrial fibrillation and cardiogenic shock, and a high probability of severe tachyarrhythmic cardiomyopathy

Krzysztof Myrda[1, 2], Wiktor Czarkowski[1], Anna Kazik[1], Aleksandra Błachut[1], Agata Kukfisz[1], Mariusz Gąsior[1, 2]

[1]2nd Department of Cardiology and Angiology, Silesian Centre for Heart Diseases, Zabrze, Poland
[2]3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

Correspondence to:
Krzysztof Myrda, MD, PhD,
2nd Department of Cardiology and Angiology,
Silesian Center for Heart Diseases,
Skłodowskiej-Curie 9,
41–800 Zabrze, Poland,
phone: +48 32 373 38 60,
e-mail: k_myrda@interia.pl

DOI: 10.33963/v.phj.103232

Received:
September 29, 2024

Accepted:
October 23, 2024

Early publication date:
November 5, 2024

We describe a case of a 47-year-old male transferred from a district cardiology department with the symptoms of refractory cardiogenic shock (CS). In the weeks preceding the current hospitalization, progression of heart failure (HF) was observed, which resulted in the development of extremely severe HF. Laboratory tests performed in the referring department showed negative myocardial necrosis markers and inflammatory parameters. Echocardiography revealed significantly impaired left ventricular ejection fraction (LVEF) with end-diastolic and end-systolic dimensions, respectively 63/57 mm, and moderate left atrial enlargement (LAVi 38 ml/m^2). At the same time, it did not show any significant valvular defects or pathological fluid in the pericardial space (Figure 1B). Significant coronary artery disease was ruled out. In addition to typical pharmacological treatment, temporary intra-aortic counterpulsation balloon support was needed. On admission, the patient presented with persistent atrial fibrillation (AF) with rapid ventricular rate (Figure 1A) and the symptoms of HF requiring temporary support with intravenous dobutamine infusion. Due to persistent symptoms of CS, amiodarone was used ineffectively, and electrical cardioversion briefly restored sinus rhythm (SR). Short-term ventricular rate control was achieved with continuous infusion of landiolol. At that time, a cardiac MRI study showed no features of myocarditis or other structural myocardial disease. LVEF of 10% was confirmed (Figure 1C). The Heart Team performed percutaneous AF ablation under the care of the cardiac surgery team with an option of emergency access to circulatory support. Accordingly, pulmonary vein isolation by cryoablation was performed in the typical fashion and was assisted by the anesthesia team. Arrhythmia interruption occurred intraoperatively. After sustained restoration of SR, the patient's condition improved significantly during the follow-up. The pressor amines were reduced and finally discontinued. The clinical improvement and the increase in LVEF to 25% already during hospitalization confirmed a severe form of tachyarrhythmic cardiomyopathy. Six months after the procedure, the patient remained free of any arrhythmias and HF symptoms. At that time, his LVEF was 46% (Supplementary material, *Video S1*).

Atrial fibrillation is the most common cause of tachyarrhythmic cardiomyopathy [1]. Permanent restoration of SR by percutaneous ablation should be the treatment of choice. In addition to an increase in LVEF, the risk of re-hospitalization for worsening HF symptoms and death of any cause is reduced [2].

To date, few cases of therapeutic ablation in patients in CS due to AF have been reported [3]. Doubts about eligibility arise from an unclear clinical picture, which indicates the tachyarrhythmic background. Furthermore, the risk of adverse events associated with the procedure is higher and increases with lower LVEF. Invasive methods of cardiovascular support may be helpful intraoperatively [4]. However, they also increase the risk of complications. The solution could be AV node ablation or urgent qualification for heart transplantation. However, pulmonary vein isolation remains a therapeutic option due to the limitations of both therapeutic approaches, given the overall clinical condition and the



Figure 1. A. Electrocardiogram performed on admission showing atrial fibrillation with rapid ventricular rate. **B.** Echocardiography ruled out valvular and pericardial disease; otherwise, it showed impaired left ventricular systolic function and moderate left atrial enlargement. **C.** Cardiac magnetic resonance imaging screen excluding cardiac disease

lack of left atrial dilatation. Preference should be given to shortening the procedure time by performing cryo-isolation of the pulmonary veins [5]. The choice of source energy differed from the descriptions available in the literature that favored radiofrequency ablation [3].

Supplementary material

Supplementary material is available at https://journals.viamedica.pl/polish_heart_journal.

Article information

Conflict of interest: None declared.

Funding: None.

REFERENCES

1. Gopinathannair R, Etheridge SP, Marchlinski FE, et al. Arrhythmia-Induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol. 2015; 66(15): 1714–1728, doi: 10.1016/j.jacc.2015.08.038, indexed in Pubmed: 26449143.
2. Marrouche NF, Kheirkhahan M, Brachmann J, et al. CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378(5): 417–427, doi: 10.1056/NEJMoa1707855, indexed in Pubmed: 29385358.
3. Volle K, Delmas C, Rollin A, et al. Successful Reversal of Severe Tachycardia-Induced Cardiomyopathy with Cardiogenic Shock by Urgent Rhythm or Rate Control: Only Rhythm and Rate Matter. J Clin Med. 2021; 10(19): 4504, doi: 10.3390/jcm10194504, indexed in Pubmed: 34640519.
4. Wybraniec MT, Hoffmann A, Wita M, et al. Impella-assisted ventricular tachycardia ablation in a patient with dilated cardiomyopathy and electrical storm. Pol Heart J. 2024; 82(10): 1021–1022, doi: 10.33963/v.phj.101843, indexed in Pubmed: 39140665.
5. Kuck KH, Brugada J, Fürnkranz A, et al. FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016; 374(23): 2235–2245, doi: 10.1056/NEJMoa1602014, indexed in Pubmed: 27042964.